ESTEVE Expands Global Reach with Acquisition of Caprelsa® for Thyroid Cancer Treatment ESTEVE has finalized an agreement with Sanofi to obtain rights to Caprelsa® across more than 50 countries, enhancing treatment options for medullary thyroid cancer.

ESTEVE Expands Global Reach with Acquisition of Caprelsa® for Thyroid Cancer Treatment #Spain #Barcelona #ESTEVE #Caprelsa #thyroid_cancer

ESTEVE Expands Its Portfolio with Acquisition of Caprelsa for Thyroid Cancer Treatment In a strategic move, ESTEVE has acquired the rights for Caprelsa® (vandetanib) to treat medullary thyroid cancer in over 50 countries, enhancing its commitment to specialized healthcare.

ESTEVE Expands Its Portfolio with Acquisition of Caprelsa for Thyroid Cancer Treatment #Spain #Barcelona #ESTEVE #Caprelsa #thyroid_cancer

ESTEVE Secures Global Rights for Caprelsa to Battle Medullary Thyroid Cancer This article discusses ESTEVE's recent acquisition of Caprelsa from Sanofi for treating aggressive medullary thyroid cancer across 50 countries.

ESTEVE Secures Global Rights for Caprelsa to Battle Medullary Thyroid Cancer #Spain #Barcelona #ESTEVE #Caprelsa #Vandetanib

ESTEVE Expands Portfolio with Acquisition of Caprelsa® to Treat Medullary Thyroid Cancer Esteve has announced its acquisition of Caprelsa®, a drug for treating medullary thyroid cancer, from Sanofi, enhancing their specialized therapies.

ESTEVE Expands Portfolio with Acquisition of Caprelsa® to Treat Medullary Thyroid Cancer #Spain #Barcelona #ESTEVE #Caprelsa #Medullary_Thyroid_Cancer